GtoPdb Ligand ID: 10550

Synonyms: Adakveo® | crizanlizumab-tmca | hSel001 [2] | SEG101
crizanlizumab is an approved drug (FDA (2019))
Compound class: Antibody
Comment: Crizanlizumab is a humanized anti-P-selectin monoclonal that was developed by Selexys Pharmaceuticals (and later acquired by Novartis) as a preventative therapy for sickle cell crises [1]. The antibody and its use are claimed in Selexys' patent WO2012088265A1 [2]. Crizanlizumab was designed to limit complement activation. In clinical trial no anti-crizanlizumab antibodies could be detected [1].
Compound class Antibody
Approved drug? Yes (FDA (2019))
International Nonproprietary Names
INN number INN
10316 crizanlizumab
Adakveo® | crizanlizumab-tmca | hSel001 [2] | SEG101
Database Links
Specialist databases
IMGT/mAb-DB 667
Other databases
GtoPdb PubChem SID 404858999
Search PubMed clinical trials crizanlizumab
Search PubMed titles crizanlizumab
Search PubMed titles/abstracts crizanlizumab